NL2013012B1 - Compounds for the treatment of chronic obstructive airway diseases. - Google Patents

Compounds for the treatment of chronic obstructive airway diseases. Download PDF

Info

Publication number
NL2013012B1
NL2013012B1 NL2013012A NL2013012A NL2013012B1 NL 2013012 B1 NL2013012 B1 NL 2013012B1 NL 2013012 A NL2013012 A NL 2013012A NL 2013012 A NL2013012 A NL 2013012A NL 2013012 B1 NL2013012 B1 NL 2013012B1
Authority
NL
Netherlands
Prior art keywords
hydroxy
tetramethylchroman
carboxamide
compound
piperazin
Prior art date
Application number
NL2013012A
Other languages
English (en)
Dutch (nl)
Inventor
Cornelis Van Der Graaf Adrianus
Schmidt Martina
Jan Willem Euverink Gerrit
Meurs Hermanus
Henk Henning Robert
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL2013012A priority Critical patent/NL2013012B1/en
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Priority to PCT/EP2015/063579 priority patent/WO2015193365A1/en
Priority to JP2016573765A priority patent/JP6711488B2/ja
Priority to US15/318,635 priority patent/US9913841B2/en
Priority to CA2952288A priority patent/CA2952288C/en
Priority to EP15730478.3A priority patent/EP3157518B1/en
Priority to ES15730478T priority patent/ES2784475T3/es
Priority to AU2015276186A priority patent/AU2015276186B2/en
Application granted granted Critical
Publication of NL2013012B1 publication Critical patent/NL2013012B1/en
Priority to US15/880,628 priority patent/US10322124B2/en
Priority to US15/880,634 priority patent/US10426771B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL2013012A 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases. NL2013012B1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NL2013012A NL2013012B1 (en) 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases.
JP2016573765A JP6711488B2 (ja) 2014-06-17 2015-06-17 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物
US15/318,635 US9913841B2 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
CA2952288A CA2952288C (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
PCT/EP2015/063579 WO2015193365A1 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
EP15730478.3A EP3157518B1 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
ES15730478T ES2784475T3 (es) 2014-06-17 2015-06-17 Compuestos de 6-hidroxi-2,5,7,8-tetrametilcromano para el tratamiento de enfermedades crónicas obstructivas de las vías respiratorias
AU2015276186A AU2015276186B2 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
US15/880,628 US10322124B2 (en) 2014-06-17 2018-01-26 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
US15/880,634 US10426771B2 (en) 2014-06-17 2018-01-26 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2013012A NL2013012B1 (en) 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases.

Publications (1)

Publication Number Publication Date
NL2013012B1 true NL2013012B1 (en) 2016-07-05

Family

ID=51358046

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2013012A NL2013012B1 (en) 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases.

Country Status (8)

Country Link
US (3) US9913841B2 (enExample)
EP (1) EP3157518B1 (enExample)
JP (1) JP6711488B2 (enExample)
AU (1) AU2015276186B2 (enExample)
CA (1) CA2952288C (enExample)
ES (1) ES2784475T3 (enExample)
NL (1) NL2013012B1 (enExample)
WO (1) WO2015193365A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2019038360A1 (en) 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
EP3672593B1 (en) 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
JP2022553549A (ja) * 2019-10-23 2022-12-23 チョン クン ダン ファーマシューティカル コーポレーション 慢性閉塞性肺疾患（ｃｏｐｄ）の予防または治療用の組成物
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222415A (ja) * 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
EP0202580A2 (en) * 1985-05-13 1986-11-26 Kuraray Co., Ltd. 3,4-Dihydrobenzopyran derivatives
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5315017A (en) * 1991-05-03 1994-05-24 Adir Et Compagnie Benzopyran compounds
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
US20050065099A1 (en) * 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041527A1 (en) 2002-11-05 2004-05-21 Ranpak Corp. System and method for making a coiled strip of dunnage
WO2005079300A2 (en) * 2004-02-13 2005-09-01 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
WO2015173195A1 (en) * 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222415A (ja) * 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
EP0202580A2 (en) * 1985-05-13 1986-11-26 Kuraray Co., Ltd. 3,4-Dihydrobenzopyran derivatives
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5315017A (en) * 1991-05-03 1994-05-24 Adir Et Compagnie Benzopyran compounds
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20050065099A1 (en) * 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells

Also Published As

Publication number Publication date
WO2015193365A1 (en) 2015-12-23
US20170151234A1 (en) 2017-06-01
US20180250294A1 (en) 2018-09-06
JP2017524674A (ja) 2017-08-31
US10426771B2 (en) 2019-10-01
US9913841B2 (en) 2018-03-13
EP3157518A1 (en) 2017-04-26
US20180280384A1 (en) 2018-10-04
AU2015276186B2 (en) 2020-09-10
CA2952288C (en) 2024-01-23
ES2784475T3 (es) 2020-09-28
AU2015276186A1 (en) 2017-01-12
EP3157518B1 (en) 2020-01-15
JP6711488B2 (ja) 2020-06-17
US10322124B2 (en) 2019-06-18
CA2952288A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
US10426771B2 (en) 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
ES2741439T3 (es) Compuestos aromáticos sustituidos
JP6826038B2 (ja) 新規モノチオール粘液溶解剤
JP2022507117A (ja) 呼吸器疾患の処理のための新規な化合物
US8765941B2 (en) Aniline derivative having anti-RNA viral activity
JP2014511897A (ja) Ｃｎｓ障害の治療におけるジベンゾチアゼピン誘導体およびその使用
EP1634606A1 (en) Drug for airway administration
CN115974832A (zh) 一种含有二硫键的n-乙酰- l-半胱氨酸衍生物及其制备方法与应用
JP2021515811A (ja) ３”，５”−ジアルコシベンゾイル−３’−アミノ−３’−デオキシアデノシン−５’−三リン酸及びその医薬用途
JPS5810577A (ja) ２−セノイルメルカプトプロピオニルグリシンのエステル、その製造法およびそれを有効成分とする医薬組成物
JP6602297B2 (ja) ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
EP4565577A1 (en) Inhibitors and uses therefor
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
CN116162128A (zh) 一种抗病毒感染的核苷衍生物及其制备方法与用途
HK40101641A (en) Anti-influenza virus derivative and the use thereof
HK40101641B (en) Anti-influenza virus derivative and the use thereof
JP2021536467A (ja) 喘息またはパーキンソン病の処置のための方法および組成物
JPWO2004112791A1 (ja) 肺疾患の治療および／または予防剤
JP2011256151A (ja) 気道異物除去用製剤及び気道異物除去方法
CN118742301A (zh) 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
JPWO2004087147A1 (ja) 肺疾患の治療および／または予防剤
WO2004087151A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PD Change of ownership

Owner name: SULFATEQ B.V.; NL

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: SULFATEQ B.V.

Effective date: 20160506